Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.
about
Making Sense of: Sensitization in SchizophreniaModels of neurodevelopmental abnormalities in schizophrenia.Animal models of schizophrenia.Evaluation of animal models of neurobehavioral disorders.Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.Posterior cerebellar vermal deficits in bipolar disorder.Contextual data integration in drug discovery.Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activationRisperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.Brain-derived neurotrophic factor and neuropsychiatric disorders.Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.Fine-mapping reveals novel alternative splicing of the dopamine transporter.A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in miceBDNF-Deficient Mice Show Reduced Psychosis-Related Behaviors Following Chronic MethamphetamineNeurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures.Risperidone alters food intake, core body temperature, and locomotor activity in mice.The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia.Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.Leading compounds for the validation of animal models of psychopathology.Activation of Dopamine D1 Receptors Regulates Dendritic Morphogenesis Through Rac1 and RhoA in Prefrontal Cortex Neurons.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Altering the course of schizophrenia: progress and perspectives.Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.Abnormalities of Dopamine D3 Receptor Signaling in the Diseased Brain.Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.Developmental timing and critical windows for the treatment of psychiatric disorders.Signaling via dopamine D1 and D3 receptors oppositely regulates cocaine-induced structural remodeling of dendrites and spines.Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats.Effects of Pro-Gly-Pro tripeptide on the dopamine system.
P2860
Q28077939-864DFC50-F291-456E-BDE8-515C6EA97BDBQ30457462-CB4302B0-EA6F-4890-A0E9-D776A91EAC31Q30462828-81DCD8EC-C3D1-409F-8B81-2D26DC0C7DCAQ30490127-079CA2C8-4935-49B4-B166-273DC4C326FAQ30524240-7F052F14-63F5-448D-ABBD-82AD1CEA5F2DQ33904292-6C00F8E6-1546-4A3C-9DCF-BF97272DC963Q34289560-A14297FB-76F9-4745-A893-BA386287EF92Q35129718-34899AC7-C691-40E2-91EE-FAD5E5B0AA10Q35166842-A0A0374B-3762-412B-9777-45E2D56EA60CQ35390344-F3EDA9A9-BDAF-46C6-A327-AEA4F9F64DACQ35847085-FEB279EB-36DD-419E-83AD-11DBAEA89660Q35889855-FB30E162-09B4-490B-8124-1156F421DB9FQ36074954-0E4AA8D2-89A8-45FA-A062-7D7176E96C70Q36579310-06907FE9-6D52-46A2-90C3-467DC5ED4CCBQ36852389-5798F000-EBEE-4D28-B703-B544761FF40AQ36877182-CD874615-F458-4427-AAA6-C1D5868CD354Q37215998-4EBD8A85-9A77-4F4D-AA1A-54DF38A6D37CQ37327529-E16BE395-B142-4944-9554-98AAFDB53141Q38057963-7E66213F-D25B-40FE-B0FF-110BD8280272Q38128733-0265701A-9B67-4A1F-BA02-C2AA906D7C3EQ38270803-60B34F90-4271-4595-B3A2-F0AEE0CEA0ADQ38314257-5A2FBA6B-3AB5-4F53-8CA8-E5CEB1BA8432Q38759421-9512131C-8EC5-4EC7-B74B-01EB197F88D0Q38846609-B8A1AEB0-0DC0-44EF-80FF-0E57E0D063C3Q41456216-8623465A-596D-46B9-B831-0F88DEC6BF24Q45369595-9A764B14-F788-4EBD-8C4E-000604513A6DQ46157390-975FE452-269C-413F-AF57-CA39F175A4CEQ47106264-83069618-9E06-4963-BCB6-00783647A2D0Q47895125-50AEEC46-C5DC-44E0-8C75-25B45FD3C747Q48215083-59D5305E-D037-4643-9B93-AB7750551238Q48374986-08EC40A8-6EF5-4733-9B60-3637A1EBE9B3Q50760353-0F069432-66B2-4E3D-82C6-D8D3C8A250F7Q50763962-0411863F-66CC-4E20-80DB-0D751711F655
P2860
Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Risperidone pretreatment preve ...... neonatal hippocampal lesions.
@ast
Risperidone pretreatment preve ...... neonatal hippocampal lesions.
@en
type
label
Risperidone pretreatment preve ...... neonatal hippocampal lesions.
@ast
Risperidone pretreatment preve ...... neonatal hippocampal lesions.
@en
prefLabel
Risperidone pretreatment preve ...... neonatal hippocampal lesions.
@ast
Risperidone pretreatment preve ...... neonatal hippocampal lesions.
@en
P2093
P2860
P356
P1476
Risperidone pretreatment preve ...... g neonatal hippocampal lesions
@en
P2093
Aaron Logue
Benjamin Taylor
Jeffrey A Welge
Jeffrey Burr
Laurel M Pritchard
Michelle M Ostrander
Neil M Richtand
Rebecca Ahlbrand
Robert K McNamara
Scott Hayes
P2860
P2888
P356
10.1038/SJ.NPP.1300791
P407
P577
2006-01-01T00:00:00Z